AQST — Aquestive Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $333.13m
- $336.79m
- $50.58m
- 29
- 27
- 78
- 41
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 52.6 | 45.8 | 50.8 | 47.7 | 50.6 |
Cost of Revenue | |||||
Gross Profit | 32.2 | 32.9 | 35.8 | 28.3 | 29.8 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 110 | 88.7 | 99.3 | 89.7 | 67.1 |
Operating Profit | -57.6 | -42.9 | -48.5 | -42.1 | -16.5 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -66.2 | -55.8 | -70.5 | -54.4 | -7.63 |
Provision for Income Taxes | |||||
Net Income After Taxes | -66.2 | -55.8 | -70.5 | -54.4 | -7.87 |
Net Income Before Extraordinary Items | |||||
Net Income | -66.2 | -55.8 | -70.5 | -54.4 | -7.87 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -66.2 | -55.8 | -70.5 | -54.4 | -7.87 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.42 | -1.66 | -1.49 | -1.12 | -0.114 |